MAP PHARMACEUTICALS, INC. EBITDA

2012-09-30: Basis Reported; EBITDA (m); Operating income -$12.62M; Depreciation and amortization (m).
2012-06-30: Basis Reported; EBITDA (m); Operating income -$13.29M; Depreciation and amortization (m).
2012-03-31: Basis Reported; EBITDA -$17.39M*; Operating income -$17.84M; Depreciation and amortization $454.00K.
2011-09-30: Basis Reported; EBITDA (m); Operating income $8.22M; Depreciation and amortization (m).

Historical EBITDA

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2012-09-30	Reported	(m)	-$12.62M	(m)	(m)	(m)	(m)	(m)	(m)	$7.86M	$5.64M	(m)
2012-06-30	Reported	(m)	-$13.29M	(m)	(m)	(m)	(m)	(m)	(m)	$7.77M	$6.40M	(m)
2012-03-31	Reported	-$17.39M*	-$17.84M	$454.00K	(m)	(m)	$1.35M	-$18.65M	(m)	$10.96M	$7.91M	(m)
2011-09-30	Reported	(m)	$8.22M	(m)	(m)	(m)	(m)	(m)	(m)	$6.72M	$5.89M	(m)
2011-06-30	Reported	(m)	-$11.22M	(m)	(m)	(m)	(m)	(m)	(m)	$7.26M	$4.80M	(m)
2011-03-31	Reported	-$15.57M*	-$15.85M	$282.00K	(m)	(m)	$1.23M	$41.55M	(m)	$11.57M	$4.84M	(m)
2010-09-30	Reported	(m)	-$13.93M	(m)	(m)	(m)	(m)	(m)	(m)	$10.01M	$3.92M	(m)
2010-06-30	Reported	(m)	-$12.15M	(m)	(m)	(m)	(m)	(m)	(m)	$8.24M	$3.91M	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2011-12-31	Reported	-$31.20M*	-$32.65M	$1.45M	(m)	(m)	$1.75M	$29.72M	(m)	$33.66M	$22.06M	(m)
2010-12-31	Reported	-$52.27M*	-$53.49M	$1.22M	(m)	(m)	$2.08M	-$49.36M	(m)	$37.77M	$15.71M	(m)
2009-12-31	Reported	-$5.49M*	-$6.97M	$1.48M	(m)	(m)	$1.32M	-$4.01M	(m)	$48.00M	$13.14M	(m)